Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt
AssigneeDeutsches Krebsforschungszentrum
InventorsChristof Niehrs, Wei Wu, Andrey Glinka, Olga Kazanskaya
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.
Claims14
A method of determining whether a binding partner of a Futrin 1 polypeptide affects Wnt signaling activity, the method comprising:
- (a) providing a mammalian cell in culture comprising the Futrin 1 polypeptide and a Wnt inducible reporter, wherein the Futrin 1 polypeptide comprises the amino acid sequence of SEQ ID NO:26, the amino acid sequence of amino acids 21-243 of SEQ ID NO:26, the amino acid sequence of amino acids 1-146 of SEQ ID NO:26, or the amino acid sequence of amino acids 21-146 of SEQ ID NO:26, wherein the Futrin 1 polypeptide is able to promote Wnt signaling;
- (b) detecting the level of reporter expression in the cell in the presence and absence of the binding partner, wherein a change in the level of reporter expression indicates that the binding partner affects the Wnt signaling.
Dependencies are inferred from the claim text.